Value proposition

Enabling Success

Sygnature Discovery, headquartered in Nottingham (UK), is a world-leading contract research organization for drug discovery. Based in the UK (Nottingham, Alderley Park, Macclesfield, Glasgow) and Canada (Montreal, Laval, Quebec) and with a staff of over 1,000, including over 900 scientists, Sygnature Discovery partners with the global pharmaceutical industry, biotechs and NfP organizations wishing to outsource part of their R&D work.

Since 2004, Sygnature Discovery has delivered more than 48 new preclinical compounds, 21 clinical compounds and 1 registered, thanks to the talents of its world-class scientists, who are named on more than 500 patents. The services offered to our customers, whether integrated or à la carte, range from protein science to in vivo pharmacology via chemistry (computational, medicinal, synthetic or process), biology and DMPK to cover numerous therapeutic areas such as oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases and more. To find out more, please visit www.sygnaturediscovery.com.

medicinal chemistry, drug discovery, chemical synthesis, assay development, CRO, chemistry, hit finding, hit to lead, lead optimisation, computational chemistry, process chemistry, biology, pharmacology, structural biology, small molecule, compound screening, biochemistry, hit to lead, lead optimization, hit finding, oncolocy, metabolic disease, inflammation, pain, neuroscience, DMPK, ADME, in vivo, crystallography, cell biology, infectious diseases, protein production, virtual screening, and target identification